Clinical trial · Observational
Clusterin Level and Polycystic Ovary Syndrome
Clusterin Level Determination and Its Association With Metabolic Syndrome in Patients With Polycystic Ovary Syndrome
NCT06601725CI-TRIAL-00080611completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clusterin, a protein involved in metabolic syndrome, insulin resistance, and metabolic disorders associated with inflammation and oxidative stress such as atherosclerosis, Alzheimer's and some malignancies, has elevated levels in metabolic syndrome, PCOS, and the combination of these two groups. Clusterin could be used as an inflammatory marker to predict PCOS and metabolic syndrome.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovulation Disorder | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clusterin level | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Phenotype A
- description
- Phenotype A was characterized by metabolic syndrome
- interventionNames
- Diagnostic Test: Clusterin level
- label
- Phenotype B
- description
- phenotype B was characterized by the absence of metabolic syndrome
- interventionNames
- Diagnostic Test: Clusterin level
- label
- Phenotype C
- description
- phenotype C was characterized by hyperandrogenism
- interventionNames
- Diagnostic Test: Clusterin level
- label
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged between 18 and 45, * natural bilateral ovaries and no functional cysts on transvaginal ultrasound. Exclusion Criteria: * who have hyperandrogenism/hyperandrogenemia * who have non-classical congenital adrenal hyperplasia (17 OHP value \>2 nmol/L) * who have thyroid disease (TSH \>5 mlU/L), * women with hyperprolactinemia (Prolactin\>30 mlU/mL) * patients taking hormonal drugs or ovulation induction agents.
References
Publications (0)
Data not yet available
No reference posted for this study.